Novo Nordisk Gets FDA CRL for Once-Weekly Insulin BLA

The FDA issued a complete response letter (CRL) to Novo Nordisk for insulin icodec — a once-weekly long-acting human insulin analogue — raising questions about the manufacturing process and the type 1 diabetes indication.
Source: Drug Industry Daily